Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. - Wikidata - awgldk - TriplyDB

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

http://www.wikidata.org/entity/Q43188537

about

The relationship between Lp(a) and CVD outcomes: a systematic review Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.Phosphocholine-containing ligands direct CRP induction of M2 macrophage polarization independent of T cell polarization: Implication for chronic inflammatory states.Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?The role of C-reactive protein in innate and acquired inflammation: new perspectives PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.Reverse Cholesterol Transport: Molecular Mechanisms and the Non-medical Approach to Enhance HDL Cholesterol.Effect of 405 nm low intensity irradiation on the absorption spectrum of in-vitro hyperlipidemia blood.Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm

P2860

Q26749317-D0284962-F49F-4B42-942E-93AF1785E89E Q26771862-B645CC00-51CA-4B20-8FB7-14D7B9B6AF89 Q33717612-0D1D6F28-1135-46E5-9189-FF4E35D7D3C8 Q37216043-4449350A-763F-46E5-BC5E-F6887E7E8B41 Q37240386-25BE563B-408D-46CE-A3CA-C5D8BE7D2189 Q37326867-D40C73B4-E7D0-4529-95F4-594C8767161D Q38748787-DB7B4055-EF08-4AC1-9DA1-42D2522B6ED4 Q38966500-7E395F2A-9DE1-4ECD-B6F3-97536F033B4F Q55004470-D2E44D1A-A98D-4F56-B9D7-0E6BE3D5E77F Q55476971-B5E404FE-8881-454F-A8FD-25DEF5852AF0 Q58886358-FEF700FE-967E-4576-9C71-4113F6FC2521

P2860

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

http://www.wikidata.org/entity/Q43188537

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

@en

type

label

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

@en

prefLabel

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

@en

P1433

Q43188537-CF5551CF-F2EF-48DB-8177-31BEFC873FA0

P1476

Q43188537-86FE0FCC-791F-4D72-8066-0B8F03172433

P2093

Q43188537-E0D19107-BD8B-4D62-81A7-B622E3C2F1D1

P2860

Q43188537-098386A0-BA7B-42FF-BBF1-D691E3DA8E9E

Q43188537-11725994-C008-4B68-8452-8653CF188E67

Q43188537-119011D8-6B07-48A3-91C1-80FE3726AEA1

Q43188537-235E7758-F167-4C78-9B02-AE8C32FB8DE8

Q43188537-27ABEF13-5566-4415-88DB-6FAC34B05329

Q43188537-2CF77AB9-FA15-4698-9BF9-495FB69D0604

Q43188537-3232C3A1-0125-4763-945D-A8D8EEB1CDB0

Q43188537-36462CA0-35B3-4E77-B615-DC5584FD50B8

Q43188537-3E86E900-0A29-402E-9A39-BAF797B0C7FE

Q43188537-41A01352-D57C-4549-9092-05194CE79623

P304

Q43188537-D7D6AC8E-A670-4DCE-A3BD-9D81609722B6

P31

Q43188537-1DE0E2D2-749C-4EAA-B81B-607F801A5A2E

P356

Q43188537-4C3133FC-C3D0-4F2F-8539-43B44AACA099

P478

Q43188537-DE788EDB-A338-4A52-966B-DC4C3F26AD7D

P50

Q43188537-46E1CFB2-840A-4F5F-9612-2FF1E08F4C26

P577

Q43188537-0E097EA1-514E-40DC-A23D-28DFA7B741AF

P5875

Q43188537-CED3241F-221F-4B99-A2B2-B7F5240669B1

P698

Q43188537-8536D2AF-75A9-42D4-A0BF-4A9509DAA449

P921

Q43188537-0C902C8C-472B-4876-91F0-CBA2E1E7C251

Q43188537-1546E58C-3A95-4552-8E15-F539C7A2BE09

Q43188537-193CA143-AF8A-4C0A-B2A2-FC7AAC73A92B

Q43188537-22C01D1E-7D26-4208-AAFA-E0590FB6C24D

Q43188537-DB2E9D47-2B3C-4A3D-8E82-12AEB2206D39

P932

Q43188537-DB6EDEEB-3583-445A-8E97-1F6D3AAFC36C

P356

S11789-015-0074-0

P1433

Clinical research in cardiology supplements

P1476

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

@en

P2093

Evelyn Orsó

http://www.w3.org/2001/XMLSchema#string

P2860

A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM

Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis

The mysteries of lipoprotein(a)

The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity

The chemokine system in diverse forms of macrophage activation and polarization

Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study.

Recommendations for the use of LDL apheresis.

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans.

P304

21-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11789-015-0074-0

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272843623

http://www.w3.org/2001/XMLSchema#string

P698

25708587

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

4361722

http://www.w3.org/2001/XMLSchema#string